Personalis (United States)

Recent papers from Personalis (United States)

1. Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II studyNature Communications · 2026
2. 41 Clinical Utility of Ultrasensitive ctDNA Detection Across the Renal Cell Carcinoma Disease Spectrum: A Multi-Cohort Retrospective StudyThe Oncologist · 2026
3. Circulating tumor DNA dynamics in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer assessed using an ultrasensitive tumor-informed assayESMO Open · 2026
4. Ultrasensitive circulating tumor DNA detection improves prognostication in triple-negative breast cancer postneoadjuvant therapyESMO Open · 2026
5. Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2 -Positive Breast CancerJAMA Oncology · 2026
6. Molecular residual disease (MRD) detection using an ultra-sensitive assay in a prospective colorectal cancer cohort: The VICTORI study.Journal of Clinical Oncology · 2026
7. Ultra-sensitive circulating tumor DNA (ctDNA) detection as predictor of survival outcomes in endometrial cancer patients undergoing frontline treatment.Journal of Clinical Oncology · 2026
8. Ultrasensitive ctDNA detection for relapse and response prediction in melanoma patients treated with immunotherapy.Journal of Clinical Oncology · 2026
9. Ultrasensitive circulating tumor DNA detection and molecular clearance as a prognostic and predictive marker in advanced renal cell carcinoma.Journal of Clinical Oncology · 2026
10. Circulating tumor DNA to enhance detection of high-risk minimal residual disease in ovarian cancer relative to second look laparoscopy.Journal of Clinical Oncology · 2026
11. Clinical validity of ultrasensitive single-digit parts per million ctDNA detection in non–small cell lung cancer.Journal of Clinical Oncology · 2026
12. Predictors of Immune Checkpoint Blockade Response in dMMR Colorectal Cancer Using an Integrated Immune-Enhanced Multi-Omics PlatformClinical Cancer Research · 2026
13. Abstract CT170: Neoadjuvant pembrolizumab stratified by tumor mutation burden in high-risk stage II-III dMMR/MSI colorectal cancer (NEOPRISM-CRC): Perioperative ultrasensitive ctDNA monitoring and tumor-infiltrating TCR repertoire for treatment response predictionCancer Research · 2026
14. Abstract 3845: Enhancing MRD detection through an ultrasensitive ctDNA test: Insights from real-world clinical dataCancer Research · 2026
15. Abstract 3851: Ultrasensitive ctDNA monitoring predicts early response of immunotherapy in recurrent metastatic non-small cell lung cancerCancer Research · 2026
16. Abstract 2588: Monitoring ESR1 and other mutations linked to resistance with a tumor-informed MRD test: Analytical validation and real world dataCancer Research · 2026
17. ErbB receptor stimulation is required for mouse Colon adenoma organoids to form cryptsGrowth Factors · 2026
18. Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patientsScientific Reports · 2026
19. The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual DiseaseJournal of Clinical Oncology · 2026
20. Use of ultra-sensitive whole genome circulating tumor DNA detection to predict early recurrence in high-risk localized RCC after nephrectomy: Preliminary real-world findings.Journal of Clinical Oncology · 2026